Thorne HealthTech, Inc. (THRN)

Thorne HealthTech, Inc. (THRN) — VMCI valuation read

THRN screens at VMCI 49/100, a 1-point gap below the Consumer Defensive sector median (50). For a mid-cap Thorne HealthTech, Inc. share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

THRN has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: THRN trades at 26.0x earnings, 44% above the Consumer Defensive median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Consumer Defensive group. Quality: ROIC of 12.0% sits 2.0pp above the Consumer Defensive median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 1.3x leaves covenant headroom, which sets the rate-cycle exposure for Thorne HealthTech, Inc..

THRN fell 2.3% over the trailing 7 days, with a -15.0% read on a 30-day basis.